Palisade Bio Inc (NASDAQ: PALI) is a clinical-stage biopharmaceutical company developing oral therapies for inflammatory bowel disease. The company has not generated significant revenue as of December 31, 2025, and funds operations through equity offerings, including warrant inducements and private placements. Its lead program, PALI-2108, is an oral prodrug in Phase 2 clinical trials targeting ulcerative colitis (UC) and Crohn's disease (CD). As of December 31, 2025, Palisade Bio held $133.4 million in cash and cash equivalents, which management believes is sufficient to fund operations through a Phase 2 primary efficacy readout for UC expected in the second half of 2027 and a Phase 2 readout for CD expected in 2028. The company is led by J.D. Finley, who serves as Chief Executive Officer and Chief Financial Officer. Palisade Bio has incurred significant operating losses and negative cash flows from operations since inception.

Revenue model

Palisade Bio generates no significant product revenue as of December 31, 2025. Operations are financed through equity issuances, including common stock offerings, warrant inducement transactions (July 2025 and prior periods), and private placements.

Products and services

PALI-2108 is the company's lead product candidate, an oral prodrug in Phase 2 clinical development for ulcerative colitis and Crohn's disease as of the 10-K filed March 20, 2026.

Customers and end markets

Target end market is patients with inflammatory bowel disease, specifically ulcerative colitis and Crohn's disease. No commercial customers exist as of December 31, 2025.

Value-chain role

Clinical-stage drug developer with no approved or commercialized products as of the filing date. The company conducts clinical trials and relies on external manufacturing and regulatory approval processes before any commercial activity.

Geographic exposure

Operations are subject to U.S. regulations including HIPAA, CCPA, and FDA oversight. The company also references GDPR and Swiss data protection rules, indicating some exposure to EU and Swiss regulatory frameworks, though primary operations are U.S.-based.

Source: SEC 10-K, filed 2026-03-20

Industry: Biological Products, (No Diagnostic Substances) Peers: CLS Holdings USA, Inc. Emmaus Life Sciences Inc AmeriCann, Inc. Artelo Biosciences Inc CANBIOLA, INC. CNS Pharmaceuticals Inc GB SCIENCES INC Johnson & Johnson Range Impact Inc